MNG686
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.563
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.410
- WNT_BETA_CATENIN_SIGNALING+0.344
- PANCREAS_BETA_CELLS+0.303
- HEDGEHOG_SIGNALING+0.284
- APICAL_SURFACE+0.280
- KRAS_SIGNALING_DN+0.260
- NOTCH_SIGNALING+0.259
- APICAL_JUNCTION+0.240
- KRAS_SIGNALING_UP+0.199
Top 10 suppressed
- MYC_TARGETS_V1-0.435
- INTERFERON_ALPHA_RESPONSE-0.413
- PROTEIN_SECRETION-0.376
- DNA_REPAIR-0.339
- MYC_TARGETS_V2-0.334
- HEME_METABOLISM-0.314
- OXIDATIVE_PHOSPHORYLATION-0.307
- PI3K_AKT_MTOR_SIGNALING-0.305
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.294
- INTERFERON_GAMMA_RESPONSE-0.288
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R297 | — | — | 0.879 |
| 2 | BS_44A3ES23 | Med | Medulloblastoma | 0.878 |
| 3 | TCGA-OL-A97C-01A-32R-A41B-07 | — | A | 0.814 |
| 4 | BS_YE1MAQYJ | EPN | EPN Tumor | 0.804 |
| 5 | a2a777ef-9294-4acf-b489-27bc17272b5e | — | — | 0.793 |
| 6 | BS_97M1E2DW | Diffuse intrinsic pontine glioma | — | 0.789 |
| 7 | SRR4296064 | — | cohortA1 | 0.780 |
| 8 | MNG891 | — | — | 0.776 |
| 9 | R216 | — | — | 0.776 |
| 10 | C3N-02143 | — | cohortA1 | 0.774 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.563 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.344 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.303 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.284 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.280 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.259 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.199 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.191 | Inavolisib | — uncovered |
| MYOGENESIS | 0.171 | Inavolisib | — uncovered |
| COAGULATION | 0.169 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.143 | Idelalisib | — uncovered |
| COMPLEMENT | 0.096 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.075 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.068 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.063 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.051 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.033 | Inavolisib | — uncovered |